pentoxifylline has been researched along with Cancer of Head in 37 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteoradionecrosis of the jaws (ORNJ) is a severe and challenging complication of head and neck radiation therapy." | 9.41 | Pentoxifylline and tocopherol for the treatment of osteoradionecrosis of the jaws. A systematic review. ( Arqueros-Lemus, M; Mariño-Recabarren, D; Martínez-Flores, R; Moraga, V; Niklander, S, 2023) |
| "This systematic review aimed to determine whether the pentoxifylline and tocopherol (PENTO) protocol effectively reduce the risk of osteoradionecrosis (ORN) in patients undergoing tooth extraction after head and neck radiotherapy." | 9.41 | Can the prophylactic use of pentoxifylline and tocopherol before dental extractions prevent osteoradionecrosis? A systematic review. ( de Campos, WG; Dos Santos Silva, AR; Júnior, CAL; Migliorati, CA; Paiva, GLA; Rocha, AC, 2023) |
| "The purpose of this study was to assess the impact of pentoxifylline and vitamin E on the incidence and severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients." | 9.30 | Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study. ( El Wakeel, L; El-Hamamsy, M; Kelany, M; Saad, AS; Sayed, R, 2019) |
| "The purpose of this study was to evaluate the healing benefit provided by the antioxidant and antifibrotic properties of pentoxifylline-tocopherol or pentoxifylline-tocopherol-clodronate in combination therapy for osteoradionecrosis." | 8.98 | Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. ( Balibrea-Del-Castillo, JM; Bescós-Atín, C; Estrugo-Devesa, A; López-López, J; Martos-Fernández, M; Saez-Barba, M, 2018) |
| "Medical management of osteoradionecrosis (ORN) via pentoxifylline, tocopherol (PENTO) and clodronate (PENTOCLO) has shown both promise and early positive outcomes." | 8.02 | The use of pentoxifylline, tocopherol and clodronate in the management of osteoradionecrosis of the jaws. ( Patel, N; Patel, S; Patel, V; Sassoon, I, 2021) |
| "In cases of advanced ORN with pathological fractures, many centres still advocate surgical resection and reconstruction." | 6.61 | Is there a role for pentoxifylline and tocopherol in the management of advanced osteoradionecrosis of the jaws with pathological fractures? Case reports and review of the literature. ( Breik, O; Briggs, K; Richardson, S; Tasfia Saief, S; Tocaciu, S, 2019) |
| "Osteoradionecrosis of the jaws (ORNJ) is a severe and challenging complication of head and neck radiation therapy." | 5.41 | Pentoxifylline and tocopherol for the treatment of osteoradionecrosis of the jaws. A systematic review. ( Arqueros-Lemus, M; Mariño-Recabarren, D; Martínez-Flores, R; Moraga, V; Niklander, S, 2023) |
| "This systematic review aimed to determine whether the pentoxifylline and tocopherol (PENTO) protocol effectively reduce the risk of osteoradionecrosis (ORN) in patients undergoing tooth extraction after head and neck radiotherapy." | 5.41 | Can the prophylactic use of pentoxifylline and tocopherol before dental extractions prevent osteoradionecrosis? A systematic review. ( de Campos, WG; Dos Santos Silva, AR; Júnior, CAL; Migliorati, CA; Paiva, GLA; Rocha, AC, 2023) |
| "The purpose of this study was to assess the impact of pentoxifylline and vitamin E on the incidence and severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients." | 5.30 | Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study. ( El Wakeel, L; El-Hamamsy, M; Kelany, M; Saad, AS; Sayed, R, 2019) |
| "The purpose of this study was to evaluate the healing benefit provided by the antioxidant and antifibrotic properties of pentoxifylline-tocopherol or pentoxifylline-tocopherol-clodronate in combination therapy for osteoradionecrosis." | 4.98 | Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. ( Balibrea-Del-Castillo, JM; Bescós-Atín, C; Estrugo-Devesa, A; López-López, J; Martos-Fernández, M; Saez-Barba, M, 2018) |
| "To review the conservative and surgical management options of osteoradionecrosis, in particular, highlighting the recent the use of anti-radiation fibrosis drugs (pentoxifylline, tocopherol and clodronate)." | 4.91 | The management of osteoradionecrosis of the jaws--a review. ( Ekanayake, K; Omer, O; Polyzois, I; Rice, N; Stassen, LF, 2015) |
| "The main components of the medical management of osteoradionecrosis (ORN) are combinations of clodronate, pentoxifylline, tocopherol, sometimes with antibiotics or chlorhexidine rinses." | 4.12 | Patients' experience and perceived concerns regarding obtaining and taking prescriptions for head and neck osteoradionecrosis. ( Lim, YBY; Rogers, SN; Willcocks, EJ, 2022) |
| "Medical management of osteoradionecrosis (ORN) via pentoxifylline, tocopherol (PENTO) and clodronate (PENTOCLO) has shown both promise and early positive outcomes." | 4.02 | The use of pentoxifylline, tocopherol and clodronate in the management of osteoradionecrosis of the jaws. ( Patel, N; Patel, S; Patel, V; Sassoon, I, 2021) |
| "Osteoradionecrosis (ORN) is a complication seen intermittently in patients who have had radiotherapy to the head and neck, and results of treatment with pentoxifylline and tocopherol (PVe) have been encouraging." | 3.83 | Prophylactic use of pentoxifylline and tocopherol in patients who require dental extractions after radiotherapy for cancer of the head and neck. ( Gadiwalla, Y; Kwok, J; McGurk, M; Patel, V; Sassoon, I; Sproat, C, 2016) |
| "Oral mucositis is a frequent side effect of cancer therapy." | 2.68 | A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. ( Burkhead, T; Garewal, HS; Koenig, LM; Vaughn, B; Verdi, CJ, 1995) |
| "The pentoxifylline was continued between chemotherapy cycles." | 2.67 | Cisplatin, cytosine arabinoside, and pentoxifylline in the treatment of squamous cell carcinoma of the head and neck. ( Cripps, MC; Fingert, H; Gerin-Lajoie, J; Laframboise, G; Lamothe, A; Stewart, DJ, 1993) |
| "In cases of advanced ORN with pathological fractures, many centres still advocate surgical resection and reconstruction." | 2.61 | Is there a role for pentoxifylline and tocopherol in the management of advanced osteoradionecrosis of the jaws with pathological fractures? Case reports and review of the literature. ( Breik, O; Briggs, K; Richardson, S; Tasfia Saief, S; Tocaciu, S, 2019) |
| "Three squamous cell carcinoma cell lines, FaDu, RPMI 2650 and SCC-61, with differences in genomic imbalance and intrinsic radiosensitivity, were irradiated with 140 cGy/min (HDRI) and 0." | 1.33 | The biological effect of pentoxifylline on the survival of human head and neck cancer cells treated with continuous low and high dose-rate irradiation. ( Danielsson, A; Delle, U; Helou, K; Karlsson, E; Mercke, C, 2005) |
| "Distant metastasis (DM) is the most common mode of recurrence among patients with advanced head and neck carcinoma treated with intra-arterial cisplatin and radiotherapy (RADPLAT)." | 1.31 | Analysis of risk factors predictive of distant failure after targeted chemoradiation for advanced head and neck cancer. ( Doweck, I; Robbins, KT; Vieira, F, 2001) |
| "Pentoxifylline is a methylxanthine derivative that produces dose-related hemorrheologic effects, lower blood viscosity, improved erythrocyte flexibility, and increased tissue oxygen levels." | 1.30 | Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. ( Futran, ND; Gwede, C; Trotti, A, 1997) |
| " In the present experiment pentoxifylline appears to be a highly effective platelet aggregation inhibitor: a dose-response curve is apparent in monkey between 6 and 24 mg/kg i." | 1.26 | Effect of phosphodiesterase inhibitors on platelet aggregation and tumor metastasis. ( Ambrus, CM; Ambrus, JL; Gastpar, H, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.70) | 18.7374 |
| 1990's | 4 (10.81) | 18.2507 |
| 2000's | 4 (10.81) | 29.6817 |
| 2010's | 16 (43.24) | 24.3611 |
| 2020's | 12 (32.43) | 2.80 |
| Authors | Studies |
|---|---|
| Marjanowski, SD | 1 |
| Maldonado, A | 1 |
| Schaller, B | 1 |
| Burkhard, JM | 1 |
| Samani, M | 1 |
| Beheshti, S | 1 |
| Cheng, H | 1 |
| Sproat, C | 3 |
| Kwok, J | 3 |
| Patel, V | 4 |
| Willcocks, EJ | 1 |
| Lim, YBY | 1 |
| Rogers, SN | 1 |
| Lombardi, N | 1 |
| Varoni, E | 1 |
| Villa, G | 1 |
| Salis, A | 1 |
| Lodi, G | 1 |
| Arqueros-Lemus, M | 1 |
| Mariño-Recabarren, D | 1 |
| Niklander, S | 1 |
| Martínez-Flores, R | 1 |
| Moraga, V | 1 |
| Paiva, GLA | 1 |
| de Campos, WG | 1 |
| Rocha, AC | 1 |
| Júnior, CAL | 1 |
| Migliorati, CA | 1 |
| Dos Santos Silva, AR | 1 |
| Young, H | 1 |
| Mellor, A | 1 |
| Cape, A | 1 |
| Mahendran, K | 1 |
| Bettoni, J | 1 |
| Tocaciu, S | 2 |
| Breik, O | 2 |
| Sayed, R | 1 |
| El Wakeel, L | 1 |
| Saad, AS | 1 |
| Kelany, M | 1 |
| El-Hamamsy, M | 1 |
| Patel, S | 1 |
| Patel, N | 1 |
| Sassoon, I | 2 |
| Dutheil, F | 1 |
| Guillemin, F | 1 |
| Biau, J | 1 |
| Pham-Dang, N | 1 |
| Saroul, N | 1 |
| Clavère, P | 1 |
| Lapeyre, M | 1 |
| Rivero, JA | 1 |
| Shamji, O | 1 |
| Kolokythas, A | 2 |
| Martin, K | 1 |
| Nathwani, S | 1 |
| Bunyan, R | 1 |
| Martos-Fernández, M | 1 |
| Saez-Barba, M | 1 |
| López-López, J | 1 |
| Estrugo-Devesa, A | 1 |
| Balibrea-Del-Castillo, JM | 1 |
| Bescós-Atín, C | 1 |
| Dhanda, J | 1 |
| Rennie, L | 1 |
| Shaw, R | 1 |
| Magremanne, M | 1 |
| Rasmussen, JT | 1 |
| Reardon, J | 1 |
| Feng, C | 1 |
| Briggs, K | 1 |
| Tasfia Saief, S | 1 |
| Richardson, S | 1 |
| Dinnoo, A | 1 |
| Bidault, F | 1 |
| Lassau, N | 1 |
| Elmaalouf, M | 1 |
| Moya-Plana, A | 1 |
| Ruffier, A | 1 |
| Janot, F | 1 |
| Benmoussa, N | 1 |
| Lyons, A | 1 |
| Osher, J | 1 |
| Warner, E | 1 |
| Kumar, R | 1 |
| Brennan, PA | 1 |
| Robard, L | 1 |
| Louis, MY | 1 |
| Blanchard, D | 1 |
| Babin, E | 1 |
| Delanian, S | 4 |
| Rice, N | 1 |
| Polyzois, I | 1 |
| Ekanayake, K | 1 |
| Omer, O | 1 |
| Stassen, LF | 1 |
| Moura, JF | 1 |
| Mota, JM | 1 |
| Leite, CA | 1 |
| Wong, DV | 1 |
| Bezerra, NP | 1 |
| Brito, GA | 1 |
| Lima, V | 1 |
| Cunha, FQ | 1 |
| Ribeiro, RA | 1 |
| Gadiwalla, Y | 1 |
| McGurk, M | 1 |
| Thariat, J | 1 |
| de Mones, E | 1 |
| Darcourt, V | 1 |
| Poissonnet, G | 1 |
| Marcy, PY | 1 |
| Guevara, N | 1 |
| Bozec, A | 1 |
| Ortholan, C | 1 |
| Santini, J | 1 |
| Bensadoun, RJ | 1 |
| Dassonville, O | 1 |
| Chatel, C | 1 |
| Porcher, R | 1 |
| Depondt, J | 2 |
| Lefaix, JL | 3 |
| Giuliari, GP | 1 |
| Sadaka, A | 1 |
| Hinkle, DM | 1 |
| Simpson, ER | 1 |
| Aygenc, E | 1 |
| Celikkanat, S | 1 |
| Kaymakci, M | 1 |
| Aksaray, F | 1 |
| Ozdem, C | 1 |
| Danielsson, A | 1 |
| Karlsson, E | 1 |
| Delle, U | 1 |
| Helou, K | 1 |
| Mercke, C | 1 |
| Ambrus, JL | 1 |
| Ambrus, CM | 1 |
| Gastpar, H | 1 |
| Verdi, CJ | 1 |
| Garewal, HS | 1 |
| Koenig, LM | 1 |
| Vaughn, B | 1 |
| Burkhead, T | 1 |
| Stewart, DJ | 1 |
| Cripps, MC | 1 |
| Fingert, H | 1 |
| Lamothe, A | 1 |
| Laframboise, G | 1 |
| Gerin-Lajoie, J | 1 |
| Futran, ND | 1 |
| Trotti, A | 1 |
| Gwede, C | 1 |
| Balla-Mekias, S | 1 |
| Doweck, I | 1 |
| Robbins, KT | 1 |
| Vieira, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Alpha Lipoic Acid on the Incidence and Severity of Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients[NCT05023863] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| The Impact of Pentoxifylline and Vitamin E on The Incidence and Severity of Radiotherapy- Induced Oral Mucositis and Dysphagia in Patients With Head and Neck Cancer[NCT02397486] | Phase 2 | 60 participants (Actual) | Interventional | 2015-05-02 | Completed | ||
| Advances in the Management of Mandibular Osteoradionecrosis: Pentoxifylline and Tocopherol as Medical Treatment[NCT02368457] | Phase 4 | 24 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment[NCT03040778] | Phase 3 | 100 participants (Anticipated) | Interventional | 2018-04-01 | Enrolling by invitation | ||
| Normal Tissue Oxygenation Following Radiotherapy[NCT00677040] | 20 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| Development of Radiation Fibrosis in Patients Treated With Pentoxyphylline and Vitamin E: a Prospective Randomized Study[NCT00583700] | Phase 2 | 54 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.[NCT00893035] | 885 participants (Actual) | Observational | 2006-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Clinical healing assessment as measured with the classification of ORN stages, area of bone exposed (mm2) and radiological findings (OPG).~Intraoral bone exposure is measured in mm2." (NCT02368457)
Timeframe: From baseline to 1, 3, 6, and 9 months of starting treatment
| Intervention | mm2 (Mean) | |||
|---|---|---|---|---|
| 1 month of starting treatment | 3 month of starting treatment | 6 month of starting treatment | 9 month of starting treatment | |
| Control Group | 15 | 15 | 15 | 15 |
| Pentoxifylline and Tocopherol | 14 | 13 | 11.5 | 10 |
"Evaluation of symptoms improvement using the LENT-SOMA scale (Late Effect Normal Tissue Task Force / Subjective, Objective, Management, Analytic scale).~To examine the LENT/SOMA scale prospectively using interviews and questionnaires~Assessments were made from baseline to 1, 3, 6 and 9 months of starting treatments. The acceptability and feasibility of using the scales was examined using compliance in completion of the questionnaires.~Maximum score: 36 Minimum score: 0~Questionnaires have been completed for 24 patients after treatment. Higher values represents worse outcome.~Scale categories:~Subjective: pain, nutritional problems, difficulty in mouth openning. Objective: bone exposure, trismus, Management: analgesic treatment, oral treatment, nutrition. Analytic: radiological findings." (NCT02368457)
Timeframe: From baseline to 1,3, 6, 9 months of starting treatment
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 1 month of starting treatment | 3 month of starting treatment | 6 month of starting treatment | 9 month of starting treatment | |
| CONTROL | 15.5 | 15.5 | 15.5 | 15.5 |
| Pentoxifylline and Tocopherol | 14.5 | 14 | 14 | 13.3 |
Transcutaneous oxygen detector is used to measure the partial pressure of oxygen. The unit detects electrolytes ionized by oxygen. The measuring electrode also heats the skin being measured to facilitate maximal bloodflow to the area. (NCT00677040)
Timeframe: One visit for 20 minutes
| Intervention | mmHg (Mean) |
|---|---|
| Subjects | 62.5 |
(NCT00677040)
Timeframe: One visit
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| late subcutaneous toxicitiy score 1 | late subcutaneous toxcity score 2 | late skin toxicity score 1 | late skin toxicity score 2 | |
| Subjects | 19 | 1 | 19 | 1 |
A primary outcome of interest is the composite Subjective, Objective, Management, and Analytic (SOMA) score at 18-month follow-up visit. Maximum score is 45, with a score of 0 being ideal and representing no treatment-related side effects at the study visit. (NCT00583700)
Timeframe: 18 month post-treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Control Arm | 1.59 |
| Intervention: Pentoxifylline & Vitamin E | 1.0 |
"Tissue compliance meter measurements of the treated breast compared to the non-treated breast were obtained at 18 months post-radiation therapy. Tissue compliance simply means how soft and pliable the breast tissue is when force is applied to it.~One physician would hold the tissue compliance meter (TCM) against the participant's skin. A standard amount of force would be applied. A second physician would read the displacement scale for a specific set of areas on the breast. The range of the scale was 0 to 60 milimeters (mm). The physician's were blineded to the participant's intervention at the time of measurement.~The final value is the difference between the untreated and the treated breast [untreated - treated]. The range of these differences was -3.3 to 7.0 mm." (NCT00583700)
Timeframe: 18 months post-treatment
| Intervention | milimeters (mm) (Mean) |
|---|---|
| Control Arm | 2.10 |
| Intervention: Pentoxifylline & Vitamin E | 0.88 |
11 reviews available for pentoxifylline and Cancer of Head
| Article | Year |
|---|---|
[Pentoxifylline and tocopherol - The importance in the treatment of osteoradionecrosis - Literature review and case report].
Topics: Head and Neck Neoplasms; Humans; Osteoradionecrosis; Pentoxifylline; Tocopherols | 2021 |
Pentoxifylline and tocopherol for the treatment of osteoradionecrosis of the jaws. A systematic review.
Topics: Head and Neck Neoplasms; Humans; Jaw; Osteoradionecrosis; Pentoxifylline; Tocopherols | 2023 |
Can the prophylactic use of pentoxifylline and tocopherol before dental extractions prevent osteoradionecrosis? A systematic review.
Topics: Head and Neck Neoplasms; Humans; Osteoradionecrosis; Pentoxifylline; Retrospective Studies; Tocopher | 2023 |
[Predictive factors for mandibular osteoradionecrosis after irradiation of head and neck cancers].
Topics: Bone Density Conservation Agents; Clodronic Acid; Drug Therapy, Combination; Head and Neck Neoplasms | 2021 |
Osteoradionecrosis: a review of pathophysiology, prevention and pharmacologic management using pentoxifylline, α-tocopherol, and clodronate.
Topics: Clodronic Acid; Drug Combinations; Head and Neck Neoplasms; Humans; Osteoradionecrosis; Pentoxifylli | 2017 |
Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review.
Topics: Clodronic Acid; Drug Combinations; Head and Neck Neoplasms; Humans; Mandibular Diseases; Osteoradion | 2018 |
Management of osteoradionecrosis of the jaws with pentoxifylline-tocopherol: a systematic review of the literature and meta-analysis.
Topics: Antioxidants; Drug Combinations; Head and Neck Neoplasms; Humans; Jaw Diseases; Osteoradionecrosis; | 2019 |
Is there a role for pentoxifylline and tocopherol in the management of advanced osteoradionecrosis of the jaws with pathological fractures? Case reports and review of the literature.
Topics: Fractures, Spontaneous; Head and Neck Neoplasms; Humans; Hyperbaric Oxygenation; Mandibular Diseases | 2019 |
The management of osteoradionecrosis of the jaws--a review.
Topics: Algorithms; Anti-Inflammatory Agents; Clodronic Acid; Fibrosis; Head and Neck Neoplasms; Humans; Hyp | 2015 |
[Teeth and irradiation: dental care and treatment of osteoradionecrosis after irradiation in head and neck cancer].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Dental Care; Fluorides; Head and Nec | 2010 |
Current treatments for radiation retinopathy.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2011 |
6 trials available for pentoxifylline and Cancer of Head
| Article | Year |
|---|---|
Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study.
Topics: Aged; Antioxidants; Deglutition Disorders; Female; Head and Neck Neoplasms; Humans; Male; Middle Age | 2019 |
Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study.
Topics: Aged; Antioxidants; Deglutition Disorders; Female; Head and Neck Neoplasms; Humans; Male; Middle Age | 2019 |
Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study.
Topics: Aged; Antioxidants; Deglutition Disorders; Female; Head and Neck Neoplasms; Humans; Male; Middle Age | 2019 |
Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study.
Topics: Aged; Antioxidants; Deglutition Disorders; Female; Head and Neck Neoplasms; Humans; Male; Middle Age | 2019 |
Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Ciprofloxacin; Clodronic Acid; Dru | 2011 |
Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Ciprofloxacin; Clodronic Acid; Dru | 2011 |
Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Ciprofloxacin; Clodronic Acid; Dru | 2011 |
Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Ciprofloxacin; Clodronic Acid; Dru | 2011 |
Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study.
Topics: Aged; Carcinoma, Squamous Cell; Chemoprevention; Head and Neck Neoplasms; Humans; Male; Middle Aged; | 2004 |
Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial.
Topics: Adult; Aged; Antimetabolites; Antioxidants; Clodronic Acid; Drug Therapy, Combination; Female; Head | 2005 |
Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial.
Topics: Adult; Aged; Antimetabolites; Antioxidants; Clodronic Acid; Drug Therapy, Combination; Female; Head | 2005 |
Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial.
Topics: Adult; Aged; Antimetabolites; Antioxidants; Clodronic Acid; Drug Therapy, Combination; Female; Head | 2005 |
Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial.
Topics: Adult; Aged; Antimetabolites; Antioxidants; Clodronic Acid; Drug Therapy, Combination; Female; Head | 2005 |
Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial.
Topics: Adult; Aged; Antimetabolites; Antioxidants; Clodronic Acid; Drug Therapy, Combination; Female; Head | 2005 |
Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial.
Topics: Adult; Aged; Antimetabolites; Antioxidants; Clodronic Acid; Drug Therapy, Combination; Female; Head | 2005 |
Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial.
Topics: Adult; Aged; Antimetabolites; Antioxidants; Clodronic Acid; Drug Therapy, Combination; Female; Head | 2005 |
Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial.
Topics: Adult; Aged; Antimetabolites; Antioxidants; Clodronic Acid; Drug Therapy, Combination; Female; Head | 2005 |
Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial.
Topics: Adult; Aged; Antimetabolites; Antioxidants; Clodronic Acid; Drug Therapy, Combination; Female; Head | 2005 |
A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over St | 1995 |
Cisplatin, cytosine arabinoside, and pentoxifylline in the treatment of squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cy | 1993 |
20 other studies available for pentoxifylline and Cancer of Head
| Article | Year |
|---|---|
Prophylactic pentoxifylline and vitamin E use for dental extractions in irradiated patients with head and neck cancer.
Topics: Head and Neck Neoplasms; Humans; Osteoradionecrosis; Pentoxifylline; Retrospective Studies; Tooth Ex | 2022 |
Patients' experience and perceived concerns regarding obtaining and taking prescriptions for head and neck osteoradionecrosis.
Topics: Chlorhexidine; Head and Neck Neoplasms; Humans; Osteoradionecrosis; Pentoxifylline; Prescriptions; T | 2022 |
Pentoxifylline and tocopherol for prevention of osteoradionecrosis in patients who underwent oral surgery: A clinical audit.
Topics: Head and Neck Neoplasms; Humans; Oral Surgical Procedures; Osteoradionecrosis; Pentoxifylline; Tocop | 2023 |
The use of liquid formulation pentoxifylline and vitamin E in both established and as a prophylaxis for dental extractions "at risk" of osteoradionecrosis.
Topics: Head and Neck Neoplasms; Humans; Osteoradionecrosis; Pentoxifylline; Retrospective Studies; Tooth Ex | 2023 |
Re: Breik O, Tocaciu K, Tasfia Saief S, Richardson S. Is there a role for pentoxifylline and tocopherol in the management of advanced osteoradionecrosis of the jaws with pathological fractures? Case reports and review of the literature.
Topics: Fractures, Spontaneous; Head and Neck Neoplasms; Humans; Osteoradionecrosis; Pentoxifylline; Tocophe | 2020 |
The need for more robust research on the role of pentoxifylline and tocopherol in the management of osteoradionecrosis of the jaws.
Topics: Fractures, Spontaneous; Head and Neck Neoplasms; Humans; Osteoradionecrosis; Pentoxifylline; Tocophe | 2020 |
The use of pentoxifylline, tocopherol and clodronate in the management of osteoradionecrosis of the jaws.
Topics: Clodronic Acid; Head and Neck Neoplasms; Humans; Jaw; Osteoradionecrosis; Pentoxifylline; Retrospect | 2021 |
Re: Pentoxifylline: a review of its use in osteoradionecrosis.
Topics: Head and Neck Neoplasms; Humans; Osteoradionecrosis; Pentoxifylline; Tocopherols | 2018 |
Current trends in the medical management of osteoradionecrosis using triple therapy.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservat | 2018 |
Successful treatment of grade III osteoradionecrosis with mandibular fracture with pentoxifylline, tocopherol and clodronate.
Topics: Clodronic Acid; Female; Head and Neck Neoplasms; Humans; Mandibular Fractures; Middle Aged; Osteorad | 2018 |
Long-term recurrences of jaw osteoradionecrosis after apparent healing with the PENTOCLO protocol.
Topics: Clodronic Acid; Drug Combinations; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Oste | 2020 |
Osteoradionecrosis--a review of current concepts in defining the extent of the disease and a new classification proposal.
Topics: Antioxidants; Free Radical Scavengers; Head and Neck Neoplasms; Humans; Hyperbaric Oxygenation; Oste | 2014 |
Medical treatment of osteoradionecrosis of the mandible by PENTOCLO: preliminary results.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Clodronic Acid; Drug Combinations; Female | 2014 |
A novel model of megavoltage radiation-induced oral mucositis in hamsters: Role of inflammatory cytokines and nitric oxide.
Topics: Animals; Cobalt Radioisotopes; Cricetinae; Cytokines; Disease Models, Animal; Guanidines; Head and N | 2015 |
Prophylactic use of pentoxifylline and tocopherol in patients who require dental extractions after radiotherapy for cancer of the head and neck.
Topics: Head and Neck Neoplasms; Humans; Neck; Osteoradionecrosis; Pentoxifylline; Platelet Aggregation Inhi | 2016 |
The biological effect of pentoxifylline on the survival of human head and neck cancer cells treated with continuous low and high dose-rate irradiation.
Topics: Carcinoma, Squamous Cell; Cell Proliferation; Cell Survival; DNA Repair; Dose-Response Relationship, | 2005 |
Effect of phosphodiesterase inhibitors on platelet aggregation and tumor metastasis.
Topics: Adenocarcinoma; Adenosine Diphosphate; Animals; Carcinoma, Ehrlich Tumor; Female; Head and Neck Neop | 1981 |
Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations.
Topics: Administration, Oral; Aged; Analgesics; Anti-Bacterial Agents; Atrophy; Debridement; Dose-Response R | 1997 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Analysis of risk factors predictive of distant failure after targeted chemoradiation for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Enzyme Inhibitors; Female; | 2001 |